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ABSTRACT
Cyclooxygenase (COX) metabolizes the polyunsaturated fatty acid arachidonic
acid (AA) to PGG2, a cyclic endoperoxide that also contains a hydroperoxide, which is
subsequently reduced to an alcohol in the enzyme to yield PGH2. Reactions catalyzed by
COX-1 are significantly influenced by lipid hydroperoxides. The tyrosyl radical that
abstracts the 13 pro(s) hydrogen from AA to initiate the COX catalytic cycle is generated
by iron-oxo derivatives in the enzyme that result from lipid hydroperoxide interaction
with heme iron. Commercial preparations of arachidonic acid (AA) contain lipid
hydroperoxides that can be separated from AA by thin layer chromatography and readily
reduced to alcohols using triphenylphosphine (TPP). The initial research objectives were
to determine by GC-MS the effect of lipid hydroperoxides contained in AA preparations
on COX-dependent metabolism of AA after TPP treatment and isolation of AA by TLC,
and the effect of TTP treatment on the products formed during COX metabolism of AA.
A novel metabolite was identified as a product of COX metabolism of AA in reactions
where TPP was present; this product is a known chemo-tactic agent that influences
immune function. The structural requirements of the reducing agent for production of the
novel metabolite were subsequently investigated.
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Chapter 1. Introduction
1.1.

Polyunsaturated Fatty Acids (PUFAs) and their Autoxidation
PUFAs have more than one double bond, hence the prefix “poly” is used before

the phrase “unsaturated fatty acids”. A few of the common PUFAs are as shown in Figure
1.

Figure 1. Polyunsaturated fatty acids with their common names and structures (1).
The formula above the name represents the number of carbon atoms versus the
number of double bonds present in a particular PUFA. For example, 20:4 indicates that
the fatty acid has 20 carbon atoms and 4 double bonds; its common name is arachidonic
acid and IUPAC name is all cis-8,11,14,17-eicosatetraenoic acid. Prefix “all cis” is used
because all the double bonds in this PUFA are “cis”(2). The double bonds are separated
by a methylene group, which is referred to as methylene-interrupted double bonds as
shown below in Figure 2.
-CH=CH-CH2-CH=CH-CH2-CH=CHFigure 2. Methylene-interrupted double bonds.
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These methylene groups that are separated by cis double bonds in a PUFA are
readily oxidized. There is a direct relation between the number of methylene groups and
the extent of the oxidation (1). Therefore arachidonic acid is more sensitive to
autoxidation than linoleic acid due to the higher number of methylene groups. Double
bonds also play an important role in auto oxidation; as the number of double bonds
increase in a PUFA, so does the complexity of the product formed (1). Autoxidation of
di-homo-γ-linolenic acid (3 double bonds) produces malondialdehyde and βhydroxyacrolien, whereas linolenic acid (2 double bonds) does not produce similar
products. Arachidonic acid that has four double bonds produces even more complex
products by intramolecular cyclization via a peroxyl radical intermediate, which is an
important step in fatty acid autoxidation as shown in Figure 3 (1).

Figure 3. Products formed by autoxidation of PUFAs.
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The monocyclic and bicyclic peroxides are autoxidation products of arachidonic
acid and are also known as isoprostanes, which are analogues of prostaglandins (PG’s).
Isoprostanes are biomarkers for oxidative stress and lipid peroxidation and are formed in
vivo primarily from arachidonic acid via free-radical-catalyzation in the absence of an
enzyme (3)
1.2.

Formation of Prostaglandins from Arachidonic Acid by Enzymatic
Transformation
Arachidonic acid is present in phospholipids and is released from the membrane

by the enzyme phospholipase A2. The released arachidonic acid is metabolized by the
enzyme cyclooxegenase-1 (COX-1) via formation of an endoperoxide (PGG2)
intermediate that is reduced to hydroperoxide (PGH2), which is further converted to
several biological mediators (structurally similar prostaglandins) as shown in Figure 4.

Figure 4. Cyclooxygenase in the synthesis of biological mediators (4).
3

1.3.

Prostaglandins (PG’s)
Prostaglandins are bioactive lipid mediators with specific physiological effects.

Prostaglandins are oxygenated fatty acids with 20-carbon atoms that contain a 5-carbonatom ring, and they differ from each other in the position/ number of double bonds or
various functional groups (keto, alcohol, etc.) present on the 5-membered ring as shown
in Table 1 (2).
Table 1. Structural differences between PGE2, PGD2, PGF2α , PGI2 and 6-Keto PGF1α and
their functions.
Prostaglandins (PGs)

Functions
Hyperalgesia

PGE2

Pyrogenic
GI tract smooth muscle contraction

PGD2

Cytotoxic Effects
Bronchoconstriction

PGF2α

Uterus Contraction
Bronchoconstriction
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Structure

PGI2

Effective Vasodilator

(Prostacyclin)
6-Keto
PGF1α(Decomposed

Inactive

product of PGI2(5))

Prostaglandins have several important physiological effects like smooth muscle
contraction and blood pressure regulation. They also play a role in pathological situations
like initiation of pain and inflammation, broncho-constriction during an asthmatic attack,
and so on. (6). The various influences on prostaglandin production and the detrimental
effects of prostaglandins on a variety of cell types and function are shown in Figure 5.
Cell injury results in the release of various inflammatory triggers including the release of
arachidonic acid from membrane lipids, which further undergoes metabolism by enzymes
(COX-1 and COX-2) to produce biologically active prostaglandins via an intermediate
(PGH2). Figure 5 also shows how the prostaglandins are transported or carried out from
the cell with the help of prostaglandin transporter. Once they are out, with help of
prostaglandin receptors (EP1, EP2, DP2 etc.) they exert their pathological functions.
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Figure 5. Detrimental effects of prostaglandins (7).
1.4.

Cyclooxygenase (COX)
Cycoloxygenase (COX) is an enzyme that catalyzes the metabolism of

arachidonic acid to form biologically significant mediators like prostaglandins (refer to
Figures 4 & 9). COX is also referred to as prostaglandin endoperoxide H synthase
(PGHS). It exists in two isoforms, COX-1, which is also known as PGHS-1, and COX-2,
also known as PGHS-2. COX-1 is the constitutive form of COX due its constant presence
in all mammalian tissues, whereas COX-2 is called the inducible form as it is produced in
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response to external factors or injury to the cell and is undetectable in most of the
mammalian tissues (8, 9).
1.5.

Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
As the name suggests, non-steroidal anti-inflammatory drugs have anti-

inflammatory properties, and the term non-steroidal is used to differentiate them from the
steroidal drugs. The most common NSAIDs are aspirin, naproxen, and ibuprofen, which
are available over the counter. The reason for pain and inflammation in most of the
situations is due to prostaglandin formation from arachidonic acid, which is catalyzed by
cyclooxygenase. NSAIDs act by inhibiting the enzyme cyclooxygenase (both COX-1 and
COX-2) to produce a therapeutic effect. Hence they are also called non-selective
NSAIDs. Cyclooxygenase plays an important role in production of a protective mucous
over the gastric mucusa (10). Hence, continuous or even intermittent use of non-selective
NSAIDs leads to the destruction of this layer with severe consequences like drug-induced
gastritis, gastric ulcer, GI bleeding, and perforation. The latest NSAIDs like Celecoxib
selectively inhibit the enzyme COX-2, which is usually responsible for pain and
inflammation, but does not affect COX-1, which is primarily responsible for the laying
down of mucous in the GI tract (11).
Normally, arachidonic acid travels through the hydrophobic channel to the
catalytic site on COX and activates the enzyme to form prostaglandins (Figure 6-A).
Aspirin blocks the access of arachidonic acid to the catalytic site by acetylation of serine
to form acetyl serine, and this process is irreversible (Figure 6-B) (12).
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A

B

Figure 6. (A) Active catalytic site of COX and its interaction with arachidonic acid. (B)
How aspirin binds to the active site of COX to inhibit the production of PGs. COX is
represented as a dimer (13).
1.6.

Role of Hydroperoxide in Activation of Cyclooxygenase
A hydroperoxide (alkyl hydroperoxide) is required to initiate the catalytic cycle

for cyclooxygenase enzyme to produce biologically significant lipid mediators (PGs).
The ferryl-oxo complex is formed from oxidation of the heme group by a hydroperoxide.
The ferryl-oxo complex then oxidizes the Tyr-385 which is present near the active site of
COX to form a tyrosyl radical. The tyrosyl radical abstracts the 13-pro(S) hydrogen from
arachidonic acid to start the catalytic cycle. After the abstraction of 13-pro(S) hydrogen
from arachidonic acid, it undergoes a radical cycle and intramolecular cyclization by
addition of two molecular oxygen atoms to form an important intermediate (PGG2) as
shown in Figure 7 (14).
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Hydroperoxide oxidizing
the heme group to ferryloxo complex

13-pro(S) hydrogen

Cyclooxgyenase
Catalytic Cycle

Figure 7. Role of Hydroperoxide in Activation of Cyclooxygenase Catalytic Cycle (14).
Figure 8 shows the role of the enzyme in hydroperoxide activation. The alkyl
hydroperoxide attacks the heme group present at the peroxidase active site. Arachidonic
acid is then attached to the cyclooxygenase active site to undergo radical and
intramolecular cyclization with the help of Tyr-385 residue.
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Arachidonate at
cyclooxygenase active
site
Heme group
at peroxidase
active site

Tyr385 between
heme group and
arachidonate to
remove13-pro(S)
hydrogen

Figure 8. Hydroperoxide, Tyr-385 and arachidonate in cyclooxygenase enzyme (12).
1.7.

Role of Lipid Hydroperoxide as an Intermediate
Lipid hydroperoxide is an intermediate in the catalytic mechanism of

cyclooxygenase (Figure 9). Arachidonic acid metabolism involves a two-step mechanism
to form prostaglandins. The first step is catalyzed by COX-1 by addition of molecular
oxygen to form a hydroperoxy (–OOH group)/endoperoxide (-O-O- group as a bicyclic
ring) intermediate also known as PGG2. In the second step, PGG2 is reduced to hydroxy
(–OH group) endoperoxide, also known as PGH2, by peroxidase activity. PGH2 then acts
as a substrate for other metabolizing enzymes to give PGE2, PGF2α, PGD2, and
prostacyclin (PGI2), and by converting the bicyclic endoperoxide to a five-membered ring
that has four different substituents. Thromboxane A2 (TXA2) has a six-membered ring
with an infused oxygen atom (oxane ring) (2, 15).
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Figure 9. Represents the metabolic pathway of arachidonic acid and the role of lipid
hydroperoxide as an intermediate for formation of prostaglandins.
Hydroperoxides thus play an important role in the overall production of
prostaglandins by activating the cyclooxygenase enzyme (section 1.6) and by acting as an
intermediate (section 1.7). Hence it is worthwhile to study the hydroperoxides in this
complicated mechanism by using mild reducing agents that do not affect the unsaturation
of arachidonic acid or the activity of cyclooxygenase to produce the biological mediators
but do reduce the hydroperoxides to alcohols.
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1.8.

Research Objectives
1. To determine, by GC-MS, the effect of lipid hydroperoxides contained in AA
preparations on COX-dependent metabolism of AA. Lipid hydroperoxides are
easily formed in AA preparations and, thus, understanding their effect on the
studies involving the COX enzyme may be confounded by their presence.
2. To study the effects of various reducing agents and other similar compounds on
the products formed during the metabolism of arachidonic acid by the enzyme
cyclooxygenase.

1.9.

Review of Literature
The production of prostaglandins depends upon the amount of hydroperoxide,

which stimulates the activity of COX-1 in arachidonic acid metabolism. In some
particular experiments, when the availability of hydroperoxide is limited or decreased by
certain reducing agents, the amount of prostaglandins generated is directly altered.
Various reducing agents have been used in the past, like glutathione peroxidase (17), tbutyl hydroperoxide, and 4-hydroxy-2,2,6,6-tetramethylpiperidinoxy radical (18), to
modify the amount of hydroperoxides in the synthesis of prostaglandins from arachidonic
acid. In another work (19), triphenylphosphine was used as a reducing agent to limit the
amount of hydroperoxides during lipid peroxidation.
In our experiments, we used a series of structurally related reducing agents such
as triphenylphosphine, and trimethylphosphine, and the oxidized product
triphenylphosphine oxide to study the influence of reducing agents on cyclooxegenase-1
metabolism of arachidonic acid.
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Chapter 2. Materials and Methodology
2.1.

Arachidonic Acid (AA)
Arachidonic acid (100 mg/mL in ethanol) was purchased from Cayman

Chemicals, Ann Arbor, and stored at -20oC, as per manufacturer’s instructions. A 1:100
dilution of arachidonic acid was made in ethanol to obtain a concentration of 1 mg/mL,
which was prepared as a stock solution and stored at -20 oC for further use.
2.2.

Triphenylphosphine (TPP)
Triphenylphosphine (CAS number: 603-35-0) was purchased from Sigma Aldrich

and stored at room temperature, as per manufacturer’s instructions. TPP is an organic
compound with three phenyl rings attached to a phosphorus atom with a nucleophilic
centre and has the ability to act as a reducing agent. A mass of 5 mg of
triphenylphosphine was dissolved in 5 mL of diethyl ether to give 1 mg/mL of
triphenylphosphine in ether and was prepared fresh before use.
2.3.

Cyclooxygenase – 1 (COX-1)
COX-1 (Ovine) 5 Kunits was supplied in 80 mM Tris-HCl, pH 8.0 with 0.1%

Tween 20 and 300 μM diethyldithiocarbamate and purchased from Cayman Chemicals,
Ann Arbor. COX-1 is extremely unstable to freeze-thaw cycling and hence was
apportioned to 10 μl aliquotes and stored at -80 oC for further use. To prevent the loss of
activity of enzyme while performing the reaction at room temperature, COX-1 was kept
on ice (0-4 oC) throughout the experiment.
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2.4.

Preparation of purified arachidonic acid (P-AA)
100 μL of 1 mg/mL of arachidonic acid was incubated with 100 μL of 1 mg/mL

of triphenylphosphine solution for 30 minutes at room temperature and evaporated under
a stream of nitrogen followed by reconstitution in 100 μL of ether. Thin layer
chromatography (TLC) was performed to obtain purified arachidonic acid.
2.5.

TLC procedure
TLC (thin layer chromatography) plates with silica gel matrix supported on glass

of 5 cm x 20 cm, with layer thickness of 250 μm and a particle size of 17 μm were
purchased from Sigma-Aldrich. The reconstituted arachidonic acid solution was spotted
as a band on the TLC plate and was developed with the solvent system of hexane, ether,
and acetic acid in a ratio of 90:10:1. The purified arachidonic acid (upper band) was
scraped from the TLC plate and extracted thrice from the silica with ether. Extracts were
combined, dried under nitrogen, and reconstituted in 100 μL of ether. Argon was
bubbled in the solution to prevent any auto-oxidation. The purified arachidonic acid (PAA) was then stored at -80 oC for further use.
2.6.

P-AA treated with TPP
100 μL of TPP solution was incubated with 100 μL of P-AA at room temperature

for 30 minutes and evaporated under nitrogen to eliminate hydroperoxides still present in
P-AA.
2.7.

COX-1 treated with TPP
100 μL of TPP solution was first evaporated completely under nitrogen, and 1 to

2 μL of COX-1 was added followed by incubation at room temperature for 30 minutes.
14

2.8.

Reaction of COX-1 with P-AA
Two solutions A and B were prepared and subsequently mixed to initiate the

reaction. Solution A contained 100 μL of 0.5 M phosphate buffer, pH 7.8, 50 μL of 1%
Tween-20: 1% octylglucoside, 50 μL of 50% glycerol, and 50μL 2.5 mM phenol.
Chemicals were mixed prior to addition of 2 μL COX-1, and the mixture was then shaken
at 37oC for 2 min. Solution B contained 100 μL of P-AA evaporated under nitrogen, and
suspended in 142 μL of deionized water.
Solution B was added to Solution A and the volume was made to 500 μL with
deionized water. The reaction was carried out on a shaker for 15 minutes at 37oC. The
reaction was stopped by plunging tubes in ice and by adding 200 μL of methanol and 100
μL of 1 M citric acid. The samples were then extracted thrice with 1 mL of ether for each
extraction. Approximately 50 grams of anhydrous sodium sulfate were added to the
samples to remove any traces of aqueous component. The organic layer (ether) was
separated from the drying agent followed by complete evaporation under nitrogen. The
products formed were further analyzed using GC/MS.
2.9.

Reaction of COX-1 and P-AA both treated with TPP
A similar reaction as in section 2.8 was performed using COX-1 treated with TPP

and P-AA treated with TPP.
2.10.

Reaction of COX-1 and P-AA both treated with MDPP/ DMPP/ TBP &
TBPO
A similar reaction as in section 2.8 was performed using COX-1 and P-AA treated

with different reducing agents like methydiphenylphosphine (MDPP)/
15

dimethylphenylphosphine (DMPP)/ tributylphosphine (TBP) and triphenylphosphine
oxide (TPPO).
2.11.

Reaction of denatured COX-1 with P-AA
The enzyme COX-1 was denatured by incubating at 60oC for 10 minutes. The

denatured COX-1 was reacted with P-AA in a similar manner as explained above.
2.12.

Preparation of derivatives for GC-MS analysis
A compound is chemically changed in a derivatization reaction so that its

properties become suitable for detection in a specific analytical method. In GC-MS,
derivatization is particularly done to impart volatility to non-volatile compounds, making
them thermally stable and reducing their polarity for better chromatographic separations.
Three different types of derivatives were prepared for analysis in the following
sequence:
1. Methyl ester derivative
The function of methyl ester derivative is to esterify carboxyl group as shown in
Figure 10.

Figure 10. The conversion of carboxyl group to acetate group by TMSD.
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Freshly prepared solutions were used for all steps of the derivatization. Solution1
contained 0.02 M trimethylsilyldiazomethane (TMSD) in heptane, which was
prepared by taking 10 µL of 2.0 M of TMSD solution in heptane (Aldrich) and
diluting with 990 µL of heptane. Solution 2 contained 20% methanol in acetone,
which was prepared by taking 600 µL methanol and diluting with 2400 µL acetone.
350 µL of each solution 1 and solution 2 were added to the sample and vortexed for
1 minute followed by incubation at room temperature for 30 minutes and complete
evaporation under nitrogen for the next derivative.
2. Oxime derivative
The function of an oxime derivative is to convert a carbonyl group to a methoxime
group as shown in Figure 11.

Figure 11. Carbonyl group is converted to methoxime group by methoxylamine HCl.
Solution 3 contained 8 mg of methoxylamine-HCl (Aldrich), which was dissolved
in 400 µL of pyridine to give 2% w/v methoxylamine-HCl in pyridine. The methyl
ester derivative was dissolved in 50 µL of the solution 3, covered with parafilm,
vortexed for one minute, and incubated in a water bath at 60 o C for 90 minutes
followed by drying under nitrogen.
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3. BSTFA derivative
Silylation of the hydroxyl group was accomplished by reaction of alcohol groups
with BSTFA (N,O -Bis(trimethylsilyl) trifluoroacetamide) as shown in Figure 12.

Figure 12. The conversion of hydroxyl group into trimethylsilyl group.
Volumes of 25 µL of pyridine and 100 µL of BSTFA reagent in 1%
trimethylchlorosilane (TMCS) was added to the sample from the oxime
derivative, covered with parafilm, vortexed for one minute, and incubated in a
water-bath at 60 o C for 60 minutes followed by drying under nitrogen. The dried
sample was re-suspended in 500 µL of ether for purification.
2.13.

Purification of samples
Samples were purified using solid phase extraction. C-18 silica columns (Waters)

were washed with hexane; samples were loaded and eluted using 2 ml of diethyl ether,
which was then evaporated completely under nitrogen. The samples were then resuspended in 100 µL of ethyl acetate for GC-MS analysis.
2.14.

GC-MS methodology
A 3800 Saturn Varian Gas Chromatograph and 2200 Varian Mass Spectrometer

were used to analyze the purified samples. A volume of 1 µL of sample was injected in
split/splitless injection with a split ratio of 1:5 and injector temperature of 200 o C into a
18

fused silica column (5% phenyl and 95% dimethylpolysiloxane) having dimensions of 30
meters length, 0.25 mm diameter, and with 0.25 µm film thickness. Helium was used as
the mobile phase. The column oven was set initially at 200 o C for 2 minutes followed by
first ramp up to 240 o C at the rate of 40 o C/minute and a second ramp up to 275 o C at the
rate of 8 o C/minute for 4.5 minutes. Electron Impact Ionization was used with an ion
trap detector. The mass range of 50 to 650 was selected and the transfer line was kept at
250 o C, while the ion trap was maintained at 180 o C.
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Chapter 3. Results
3.1.

Reaction of COX-1 with P-AA
The aim of this reaction was to confirm the products formed by arachidonic acid

metabolism via COX-1. Two major peaks in the chromatogram were seen at retention
times of 6.10 and 7.30 minutes after injection of the sample on the GC column as shown
in Figure 13.

Reaction of COX-1 with P-AA

6 –Keto PGF1α
PGE2

Derivatized Standard for PGE2

Figure 13. Gas chromatogram of derivatized products formed when P-AA is incubated
with COX-1 is shown above the chromatogram of derivatized standard PGE2.
The product with a retention time of 7.30 minutes was identified as PGE2 and
confirmed by comparison to a derivatized PGE2 standard. The peak at 6.10 minutes was
identified as 6-keto PGF1α by comparing it with a derivatized standard of 6-keto PGF1α as
shown in Figure 14.
20

A
6 –Keto PGF1α

Derivatized Standard
for 6 –Keto PGF1α

B
Reaction of COX-1
with P-AA

Figure 14. (A) Gas chromatogram of derivatized standard 6-Keto PGF1α. (B) Gas
chromatogram of derivatized products formed at 6.10 minutes when P-AA is incubated
with COX-1.
The derivatization reaction of PGE2 and 6-keto PGF1α is as shown in Figure 15 (A) and
(B)
A
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B

Figure 15. Scheme for synthesis of the methyl ester-oxime-silylated derivative of (A)
PGE2 and (B) 6-keto PGF1α.

Base Peak
PGE2 by reaction of COX-1
with P-AA

Base Peak
Derivatized Standard for
PGE2

Figure 16. Comparison between the mass spectra of the product formed at 6.13 min with
derivatized PGE2 standard.
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Formation of PGE2 and 6-keto PGF1α during P-AA metabolism by COX-1 was
confirmed by comparing mass spectra with derivatized standards as shown above in
Figure 16 and Figure 17.
The circles on the mass spectra indicate the major fragment (Base peak) and
daughter fragments that are common to both mass spectra.

Base Peak
6-Keto PGF1αformed by reaction
of COX-1 with P-AA

Base Peak
Derivatized Standard for 6-Keto
PGF1α

Figure 17. Comparison between the mass spectra of the compound formed at 6.14 min
with derivatized 6-keto PGF1α standard.
3.2.

Reaction of denatured COX-1 and P-AA
The aim of this reaction was to confirm that the production of PGE2 and 6-keto

PGF1α from arachidonic acid catalyzed by COX-1 is a function of the enzyme rather than
a contamination in commercially available arachidonic acid preparations (refer to Figure
23

18 ([A] and [B]). Indeed, no peaks corresponding to those found to be present in the
chromatogram were evident when the intact COX-1 was replaced with the heat-denatured
form.

Gas Chromatogram
for reaction of
denatured COX-1
with P-AA

Not PGE2

No 6 -Keto PGF1α

Mass Spectrum of the
Non Gaussian Peak at
7.38 minutes

Figure 18. (A) Gas chromatogram and (B) A mass spectrum of the products of a reaction
between the denatured COX-1 and P-AA, showing absence of peaks and ions
respectively, concluding absence of 6-Keto PGF1αand PGE2.
3.3.

Reaction of COX-1 and P-AA both treated with TPP
The aim of this reaction was to reduce any peroxide present in COX-1 and P-AA

by treating both with TPP. The chromatogram obtained by this reaction was similar to
24

Figure 13. Interestingly, an additional peak at a retention time of 5.16 minutes was
observed in the chromatogram, which was not present in the chromatograms for COX
reactions conducted in the absence of added TPP.
A
12-HETE

6 -Keto PGF1α
PGE2

Reaction of COX-1 with P-AA
both treated with TPP

B
Derivatized Standard of
12-HETE

Figure 19. (A) Gas chromatogram of derivatized products formed when TPP-treated
COX-1 was incubated with TPP treated P-AA. (B) Gas chromatogram of derivatized
standard 12-HETE.
A new peak in the chromatogram at a retention time of 5.16 minutes indicates the
production of a novel metabolite that was tentatively identified as12hydroxyeicosatetraenoic acid (12-HETE) by comparison with 12-HETE standard as
shown in Figure 19 (A) and (B).
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The derivatization reaction of 12-HETE is shown in Figure 20.

Figure 20. Scheme for synthesis of methyl ester-silylated derivative of 12hydroxyeicosatetraenoic acid (12-HETE).
Formation of 12-HETE was further confirmed by comparing the mass spectrum with
the derivatized standard of 12-HETE. The match between the base peaks with m/z 262.2
as well as the other ions with m/z of 51.0, 77.0, 108.1, 152.2. 183.2, 445.2, and 502.6 in
both the spectra, confirms the formation of 12-HETE as shown in Figure 21.
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Base Peak

Derivatized Standard for
12-HETE

Base Peak
12-HETE formed by reaction of
COX-1 with P-AA both treated
with TPP

Figure 21. Comparison between the mass spectra of derivatized 12-HETE formed by the
reaction of COX-1 with P-AA both treated with TPP and the standard derivatized 12HETE.
3.4.

Derivatization of P-AA treated with TPP
P-AA, treated with TPP, was derivatized and analysed using GC-MS. No peak

corresponding to 12-HETE was seen conforming that the production of 12-HETE is
dependent on COX-1 and not on P-AA treated with TPP alone as shown in Figure 22.
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Derivatized P-AA treated with TPP
No 12-HETE

12-HETE
Derivatized Standard of 12-HETE

Figure 22. Chromatogram for derivatized P-AA treated with TPP and derivatized
standard 12-HETE.
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Chapter 4. Interpretation and Comparison of Results
4.1.

Purified Arachidonic Acid P- AA
P- AA was prepared as described in section 2.5 by using TLC. Two TLC plates

were used to show the commercially purchased AA and AA that was treated with TPP,
i.e. P - AA. Commercially purchased AA was spotted as a band on plate one and AA
treated with TPP was spotted as a band on plate two. The plates were developed in the
same chamber and phosphomolybdic acid was used to stain the plates to visualize the
compounds as shown in Figure 23.

Hydroperoxides
reduced to alcohols
Arachidonic Acid +
Arachidonic Acid
with Hydroperoxide

Plate 1

Purified
Arachidonic Acid

Plate 2

Figure 23. Thin layer chromatography plates of arachidonic acid samples before (Plate 1)
and after (Plate 2) treatment with triphenylphosphine.
Plate 1 showed a single band corresponding to the commercially available AA
that has hydroperoxides in it. However, Plate 2 shows two bands. The lower band
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corresponds to purified AA while the upper band corresponds to the alcohol formed due
to reduction of hydroperoxides present in AA by TPP.
4.2.

Comparison of products formed from reaction of COX-1 with P - AA and
reaction of TPP treated COX-1 with TPP treated P - AA
Two major observations were seen in this comparison as shown in Figure 24.

First, the amount of PGE2 produced by reaction of COX-1 with P - AA treated with TPP
was not appreciably altered when compared to reaction of untreated COX-1 with P - AA.
Production of a novel metabolite 12- HETE was seen in the reaction of TPP-treated
COX-1 with TPP-treated P - AA.

Reaction of COX-1 with P - (AA) without TPP
and both treated with TPP
Amount of PGE2is
not altered with or
without TPP

12-HETE by TPP

No 12-HETE
without TPP

Figure 24. Comparison of GC Chromatogram for products formed from reaction of COX1 with P - AA and reaction of TPP-treated COX-1 with TPP-treated P - AA
4.3.

Comparison of TPP with other reducing agents
To determine the specificity of TPP in the production of 12-HETE, other reducing
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agents like methyl diphenylphosphine (MDPP) and di-methyl phenylphosphine (DMPP)
were used instead of TPP (refer to Figure 25).

Reaction of COX-1 with P - AA both treated with TPP,
MDPP or DMPP

12-HETE by
TPP, MDPP
& DMPP

6-Keto PGF1α

PGE2

Enlarged portion of 12-HETE peak

12-HETE by TPP
12-HETE by MDPP

No 12-HETE by
DMPP

Figure 25. Comparison of GC chromatogram for products formed from reaction of COX1 with P - AA both treated with TPP, MDPP or DMPP.
A few major observations were made. First, the amount of PGE2 produced by
using TPP, MDPP, or DMPP in the reaction of COX-1 and AA both treated with these
chemicals were the same. Second, a similar peak to 12-HETE was seen with reaction of
MDPP. Third, the amount of 12-HETE produced by MDPP was appreciably lower than
the amount produced by TPP. Finally, virtually no 12-HETE was seen with reaction of
DMPP. To confirm the production of 12-HETE by MDPP, mass spectra were compared
as shown in Figure 26.
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Mass Ions produced by Derivatized
Standard for 12-HETE

Mass Ions produced by Reaction
COX-1 + P- AA both treated with TPP
for 12-HETE

Mass Ions produced by Reaction
COX-1 + P- AA both treated with
MDPP for 12-HETE

Mass Ions produced by Reaction
COX-1 + P- AA both treated
with DMPP for 12-HETE

Figure 26. Comparison of mass ions for 12-HETE produced by standard12-HETE and by
the reaction COX-1 with P- AA both treated with TPP, MDPP, or DMPP
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4.4.

Comparison of TPP with other oxide reducing agents
Reactions of COX-1 with P - AA both treated with tributylphosphine (TBP),

tributylphosphine oxide (TBPO), and triphenylphosphine oxide (TPPO) were carried out
to see whether 12-HETE is produced with oxide reducing agents.
No 12-HETE was formed with the reactions of TBP, TBPO or TPPO, as seen in
Figure 27.

Treated with
TBPO

No 12-HETE

Treated with
TPPO
PGE2
6-Keto PGF1α

12-HETE

Treated with
TBP

Treated with
TPP

Figure 27. Comparison of gas chromatogram of products of reaction between COX-1 and
P-AA both treated with 1. TBPO, 2. TPPO, 3. TBP, and 4. TPP.
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Chapter 5. Conclusions
Thin layer chromatography clearly indicates that arachidonic acid, when treated
with a reducing agent like triphenylphosphine, produces lipid alcohols; these lipid
alcohols are produced due to the presence of lipid hydroperoxides in commercially
available arachidonic acid preparations as shown in Figure 28.

Figure 28. Conversion of arachidonic acid 5-hydroperoxide to arachidonic acid 5hydroxy by triphenylphosphine. Triphenylphosphine oxide is formed as a by-product.
The incubation of triphenylphosphine and methyl diphenylphosphine with COX-1
and purified arachidonic acid resulted in a new metabolite, 12-HETE, and did not
appreciably affect the production of PGE2 and 6-Keto PGF1α. However, when the same
experiment was conducted treating both reactants with tributylphosphine,
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tributylphosphine oxide or triphenylphosphine oxide, no 12-HETE was produced and
COX-1 dependent production of PGE2 and 6-Keto PGF1αwas still supported.
The presence of hydroperoxides in a reaction of arachidonic acid with COX
ensures that the cyclooxygenase enzyme remains in a catalytically active state and the
conversion of arachidonic acid to physiologically significant prostaglandins proceeds in
an uninhibited fashion. Hence it is imperative to control the presence of hydroperoxides
in the reaction of arachidonic acid with COX. This work shows that removal of
hydroperoxides by TPP controls their presence in the reaction and, thus, controls the
production of biologically significant prostaglandins.
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Chapter 6. Discussion
Arachidonic acid conversion can be catalyzed by two different enzymes,
cyclooxygenase and lipooxygenase, producing distinct biologically significant lipid
mediators. Arachidonic acid, when metabolized by the enzyme 12-lipooxygenase,
produces an intermediate called 12-HETE. The production of 12-HETE is not known to
occur when arachidonic acid is metabolized by the enzyme cyclooxygenase. An attempt
at verification of 12-HETE production was done by HPLC-MS in collaboration with Dr.
Paul Kennedy at Cayman Chemical, Ann Arbor. Preliminary results suggest that 12HETE is not formed during the metabolism of AA by COX-1 in the presence of TPP
(Steve Pernecky, personal communication). Further experiments will have to be
conducted to determine whether the preparation of derivatives for GC-MS analysis may
have yielded a product with a similar chromatography and mass spectrum of 12-HETE.
The results of the current study indicated that 12-HETE is produced as a result of
arachidonic acid metabolism catalyzed by COX-1 in the presence of TPP or MDPP. This
is supportive of the possibility that TPP or MDPP stimulates a novel activity in the
enzyme (COX-1) that results in production of 12-HETE. Since the reducing agents, TBP,
TBPO, or TPPO, do not support production of 12-HETE, this suggests that the generation
of the novel metabolite (12-HETE) is not attributed to the reductive capacity of the
reducing agent. In addition, the control reaction with denatured COX indicates that the
intact enzyme plays some role in the production of 12-HETE. 12-HETE is also a product
of non-enzymatic oxidation of arachidonic acid, but in this study arachidonic acid was
treated with a reducing agent (TPP) to remove hydroperoxides so that the chances of nonenzymatic oxidation of arachidonic acid was eliminated.
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The hypothetical pathway for the production of 12-HETE is as shown in Figure
29.

Figure 29. 12-HETE can be formed via formation of 12-HpETE or directly to 12-HETE.
Both pathways involve reaction of P- AA and COX-1 in presence of TPP/MDPP
The production of 12-HETE is referred to as a novel metabolite because 12-HETE
has not been previously observed in the metabolic pathway of arachidonic acid catalyzed
by COX-1.
The structure of the reducing agent might have an important role in supporting the
production of 12-HETE (refer to Figure 30).

TPP

MDPP

Figure 30. Structure comparison of TPP and MDPP
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TPP has three phenyl rings attached to a phosphorus atom, whereas MDPP has
two phenyl rings, the third phenyl ring being replaced by a methyl group. This indicates
that at least two phenyl rings attached to one phosphorous atom are needed to produce
12-HETE, as other reducing agents with slight dissimilarity in structure (refer to Figure
31) don’t produce 12-HETE.

DMPP

TBPO

TBP

TPPO

Figure 31. Structure of DMPP, TBPO, TBP, and TPPO.
Some natural and dietary compounds, which have structural similarities to TPP
and MDPP, can control the function of the enzyme to produce 12-HETE, which is known
as a chemotactic agent, influencing the immune system (20, 21). Hence it is important to
38

explore the structurally similar natural/dietary compounds to see whether they influence
the catalytic activity of enzyme (metabolism of arachidonic acid via COX-1) to produce
12-HETE. Our work thus explores a novel pathway in arachidonic acid metabolism
towards the synthesis of HETE through COX-1.
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